183 related articles for article (PubMed ID: 37895923)
1. A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence.
Festuccia C; Corrado M; Rossetti A; Castelli R; Lodola A; Gravina GL; Tognolini M; Giorgio C
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895923
[TBL] [Abstract][Full Text] [Related]
2. UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling.
Giorgio C; Allodi M; Palese S; Grandi A; Tognolini M; Castelli R; Lodola A; Flammini L; Cantoni AM; Barocelli E; Bertoni S
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34074058
[TBL] [Abstract][Full Text] [Related]
3. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice.
Festuccia C; Gravina GL; Giorgio C; Mancini A; Pellegrini C; Colapietro A; Delle Monache S; Maturo MG; Sferra R; Chiodelli P; Rusnati M; Cantoni A; Castelli R; Vacondio F; Lodola A; Tognolini M
Oncotarget; 2018 May; 9(36):24347-24363. PubMed ID: 29849945
[TBL] [Abstract][Full Text] [Related]
4. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.
Giorgio C; Hassan Mohamed I; Flammini L; Barocelli E; Incerti M; Lodola A; Tognolini M
PLoS One; 2011 Mar; 6(3):e18128. PubMed ID: 21479221
[TBL] [Abstract][Full Text] [Related]
5. Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice.
Ferlenghi F; Castelli R; Scalvini L; Giorgio C; Corrado M; Tognolini M; Mor M; Lodola A; Vacondio F
J Pharm Biomed Anal; 2020 Feb; 180():113067. PubMed ID: 31891876
[TBL] [Abstract][Full Text] [Related]
6. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Anti-Tumor Activity of Small Molecules Targeting Eph/Ephrins in APC
Corrado M; Giorgio C; Barocelli E; Marzetti GV; Cantoni AM; Di Lecce R; Incerti M; Castelli R; Lodola A; Tognolini M
Pharmaceuticals (Basel); 2020 Apr; 13(4):. PubMed ID: 32316101
[TBL] [Abstract][Full Text] [Related]
8. Protection by the Eph-Ephrin System Against Mesenteric Ischemia-Reperfusion Injury.
Vivo V; Zini I; Cantoni AM; Grandi A; Tognolini M; Castelli R; Ballabeni V; Bertoni S; Barocelli E
Shock; 2017 Dec; 48(6):681-689. PubMed ID: 28472014
[TBL] [Abstract][Full Text] [Related]
9. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
10. Δ(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system.
Castelli R; Tognolini M; Vacondio F; Incerti M; Pala D; Callegari D; Bertoni S; Giorgio C; Hassan-Mohamed I; Zanotti I; Bugatti A; Rusnati M; Festuccia C; Rivara S; Barocelli E; Mor M; Lodola A
Eur J Med Chem; 2015 Oct; 103():312-24. PubMed ID: 26363867
[TBL] [Abstract][Full Text] [Related]
11. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer.
Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC
Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975
[TBL] [Abstract][Full Text] [Related]
12. Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin.
Rusnati M; Paiardi G; Tobia C; Urbinati C; Lodola A; D'Ursi P; Corrado M; Castelli R; Wade RC; Tognolini M; Chiodelli P
Cancer Gene Ther; 2022 Jul; 29(7):908-917. PubMed ID: 34426652
[TBL] [Abstract][Full Text] [Related]
13. Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT.
Zhao Y; Cai C; Zhang M; Shi L; Wang J; Zhang H; Ma P; Li S
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2013-2023. PubMed ID: 33772606
[TBL] [Abstract][Full Text] [Related]
14. May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
Psilopatis I; Karniadakis I; Danos KS; Vrettou K; Michaelidou K; Mavridis K; Agelaki S; Theocharis S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613532
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
[TBL] [Abstract][Full Text] [Related]
16. In PC3 prostate cancer cells ephrin receptors crosstalk to β1-integrins to strengthen adhesion to collagen type I.
Yu M; Wang J; Muller DJ; Helenius J
Sci Rep; 2015 Feb; 5():8206. PubMed ID: 25644492
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction.
Giorgio C; Incerti M; Corrado M; Rusnati M; Chiodelli P; Russo S; Callegari D; Ferlenghi F; Ballabeni V; Barocelli E; Lodola A; Tognolini M
Biochem Pharmacol; 2018 Jan; 147():21-29. PubMed ID: 29129483
[TBL] [Abstract][Full Text] [Related]
18. Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids.
Guidetti L; Castelli R; Scalvini L; Ferlenghi F; Corrado M; Giorgio C; Tognolini M; Lodola A
Pharmaceuticals (Basel); 2022 Jan; 15(2):. PubMed ID: 35215250
[TBL] [Abstract][Full Text] [Related]
19. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB
Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556
[TBL] [Abstract][Full Text] [Related]
20. A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors.
Noberini R; De SK; Zhang Z; Wu B; Raveendra-Panickar D; Chen V; Vazquez J; Qin H; Song J; Cosford ND; Pellecchia M; Pasquale EB
Chem Biol Drug Des; 2011 Oct; 78(4):667-78. PubMed ID: 21791013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
